Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 6—June 2017

Sporadic Creutzfeldt-Jakob Disease in 2 Plasma Product Recipients, United Kingdom

Patrick Urwin, Kumar Thanigaikumar, James W. Ironside, Anna Molesworth, Richard S. Knight, Patricia E. Hewitt, Charlotte Llewelyn, Jan Mackenzie, and Robert G. WillComments to Author 
Author affiliations: University of Edinburgh Western General Hospital, Edinburgh, Scotland, UK (P. Urwin, J.W. Ironside, A. Molesworth, R.S. Knight, J. Mackenzie, R.G. Will); University Hospital Lewisham, London, UK (K. Thanigaikumar); National Health Service Blood and Transplant, London (P.E. Hewitt); National Health Service Blood and Transplant/Public Health England Epidemiology Unit, Cambridge, UK (C. Llewelyn)

Main Article

Table 2

Selected characteristics and clinical features of the 2 patients with sporadic Creutzfeldt-Jakob disease described in cases 1 and 2, United Kingdom, 2014*

Characteristic/clinical feature
Case 1
Case 2
Patient age, y/sex
Ataxia, cognitive impairment, visual impairment, myoclonus
Somnolence/depression, dysphasia, cognitive impairment, myoclonus/ataxia
Magnetic resonance imaging + +
Electroencephalogram + Slow activity
Cerebrospinal fluid 14–3–3 assay + +
Genotype MM MM
Diagnosis Definite sCJD Definite sCJD
Duration 3 mo 7 mo

*RT-QuIC, real-time quaking-induced conversion; sCJD, sporadic Creutzfeldt-Jakob disease.

Main Article

Page created: May 11, 2017
Page updated: May 11, 2017
Page reviewed: May 11, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.